Entrada Therapeutics, Inc. SEC filings TRDA

Entrada Therapeutics, Inc. has 472 filings in SEC EDGAR's recent list, going back to Nov 10, 2016. Its latest annual report, Form ARS, was filed on Apr 24, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 5, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 14, 2026 (regulation fd disclosure, other events). The company's fiscal year ends on December 31.

Form Description Filed Period
DEFA14A Additional proxy material Apr 29, 2026 —
DEFA14A Additional proxy material Apr 24, 2026 —
DEF 14A Proxy statement Apr 24, 2026 Jun 10, 2026
DEFA14A Additional proxy material Jun 3, 2025 —
DEFA14A Additional proxy material Apr 25, 2025 —
DEF 14A Proxy statement Apr 25, 2025 Jun 11, 2025
DEFA14A Additional proxy material Apr 29, 2024 —
DEF 14A Proxy statement Apr 29, 2024 Jun 13, 2024
PRE 14A Preliminary proxy statement Apr 19, 2024 Jun 13, 2024
DEFA14A Additional proxy material Apr 25, 2023 —
DEF 14A Proxy statement Apr 25, 2023 Jun 8, 2023
DEFA14A Additional proxy material Apr 19, 2022 —
DEF 14A Proxy statement Apr 19, 2022 Jun 2, 2022

Showing 13 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
TRDA (Nasdaq)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Boston, MA
SEC filer status
, Emerging growth company
SEC CIK
1689375
Former names
CycloPorters, Inc. (until Nov 10, 2016)

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.